Diabetologie und Stoffwechsel 2025; 20(S 01): S98-S99
DOI: 10.1055/s-0045-1807553
Abstracts | DDG 2025
Poster
Posterwalk 15: Sonstige Themen

Early Weight Loss and Cardiometabolic Parameters in Tirzepatide-Treated Participants in SURMOUNT 1-2

T Thethi
1   AdventHealth, Translational Research Institute and AdventHealth Diabetes, Obesity and Endocrinology Institute, Endocrinologist, Orlando, United States
,
A Kokkinos
2   First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, First Department of Propaedeutic Internal Medicine, Athens, Greece
,
M McKean-Matthews
3   Eli Lilly and Company, CMH, Indianapolis, United States
,
C Lee
4   Eli Lilly and Company, Global Medical Affairs Obesity/NILEX, Indianapolis, United States
,
L M Neff
5   Eli Lilly and Company, Global Medical Affairs-Obesity, Indianapolis, United States
,
C Mast
6   Eli Lilly and Company, Global Med Comm-DBU, Indianapolis, United States
,
A Rodriguez
7   Eli Lilly and Company, Next Generation Incretins (NILEX), Indianapolis, United States
,
A Stefanski
8   Eli Lilly and Company, CWM Development, Indianapolis, United States
,
A Bartee
9   Eli Lilly and Company, Next Generation Incretins Development, Indianapolis, United States
,
U Lindner
10   Klinikum Chemnitz, Chemnitz, Germany, Internal Medicine and Endocrinology and Diabetology, Chemnitz, Germany
› Author Affiliations
› Further Information
Also available ateRef
 
 

    Was early weight reduction associated with greater improvements in cardiometabolic parameters (CPs) in participants treated with tirzepatide (TZP) in SURMOUNT (SM)-1 and SM-2 trials?

    Methods: Post hoc analyses included TZP-treated participants with obesity or overweight with≥1 weight related complication in SM-1 (n=1775) and with type 2 diabetes in SM-2 (n=609) categorized as early responders (≥5% weight reduction) or non-early responders (<5% weight reduction) at Week 8. Analyses used the efficacy estimand and assessed variables based on analysis of variance and logistic regression.

    Results: In SM-1, early responders (n=1103, 62.1%) had significantly greater improvements in body weight (BW) and CPs from baseline (BL) to Week 72 (W72) vs. non-early responders (n=672, 37.9%): BW (-23.3% vs. -14.6%, p<0.001), systolic blood pressure (SBP) (-9.8 vs. -5.6 mmHg, p<0.001), diastolic blood pressure (DBP) (-6.0 vs. -4.2 mmHg, p<0.001), triglycerides (TGs) (-30.9% vs. -23.0%, p<0.001), HDL (10.0% vs. 3.8%, p<0.001), and ALT (-31.1% vs. -25.1%, p<0.001). In SM-2, early responders (n=247, 40.6%) achieved a greater reduction in HbA1c from BL to W72 compared to non-early responders (n=362, 59.4%) (-2.5% vs. -2.0%, p<0.001), with greater proportions achieving HbA1c<5.7% (69.7% vs. 41.2%). Early responders had significantly greater improvements in CPs from BL to W72 vs. non-early responders: BW (-20.0% vs. -10.8%, p<0.001), SBP (-8.4 vs. -6.2 mmHg, p=0.04), DBP (-3.7 vs. -2.0 mmHg, p=0.012), TGs (-34.5% vs. -23.9%, p<0.001), HDL (13.4% vs. 4.8%, p<0.001) and ALT (-38.7% vs. -28.4%, p<0.001).

    Conclusion: In SM-1-2, TZP-treated participants with obesity or overweight achieved significant weight reduction and improved CPs compared to BL, regardless of early weight reduction response category; however, in these post-hoc analyses, early responders achieved greater improvements in CPs compared to non-early responders.


     

    Interessenkonflikt

    MM, CL, LN, CM, AR, AS, and AB are employees and shareholders of Eli Lilly and Company. T.K.T. is on the speaker&apos;s bureau for Novo Nordisk and is one of the US national leads for the Semaglutide Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes (SOUL) trial (NCT03914326).

    Publication History

    Article published online:
    28 May 2025

    © 2025. Thieme. All rights reserved.

    Georg Thieme Verlag KG
    Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany